Hormone replacement therapy after breast cancer: a systematic review and quantitative assessment of risk.

PURPOSE Hormone replacement therapy (HRT) is typically withheld from women with breast cancer because of concern that it might increase the risk of recurrence. The purpose of this study was to quantify the risk of recurrent breast cancer associated with HRT among breast cancer survivors. METHODS We performed a systematic literature review through May 1999, calculating the relative risk (RR) of breast cancer recurrence in each study by comparing the number of recurrences in the HRT group to those in the control group. In studies that did not contain a control group, we constructed one by estimating the expected number of recurrences based on data from the Early Breast Cancer Trialists' Collaborative Group, adjusting for nodal status and disease-free interval. RRs across all studies were combined using random-effects models. RESULTS Of the 11 eligible studies, four had control groups and included 214 breast cancer survivors who began HRT after a mean disease-free interval of 52 months. Over a mean follow-up of 30 months, 17 of 214 HRT users experienced recurrence (4.2% per year), compared with 66 of 623 controls (5.4% per year). HRT did not seem to affect breast cancer recurrence risk (RR = 0.64, 95% confidence interval [CI], 0.36 to 1.15). Including all 11 studies in the analyses (669 HRT users), using estimated control groups for the seven uncontrolled trials, the combined RR was 0.82 (95% CI, 0.58 to 1.15). CONCLUSION Although our analyses suggest that HRT has no significant effect on breast cancer recurrence, these findings were based on observational data subject to a variety of biases.

[1]  D. Grabrick,et al.  Risk of breast cancer with oral contraceptive use in women with a family history of breast cancer. , 2000, JAMA.

[2]  J. Kirchner,et al.  Management of the climacteric , 2000, Postgraduate medicine.

[3]  J. Marsden.  Hormone-replacement therapy and breast cancer. , 2002, The Lancet. Oncology.

[4]  O. Olopade,et al.  Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. , 1999, Journal of the National Cancer Institute.

[5]  G. Hortobagyi,et al.  Estrogen replacement therapy after localized breast cancer: clinical outcome of 319 women followed prospectively. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  S. Bebar,et al.  A case-control study of hormone replacement therapy after primary surgical breast cancer treatment. , 1999, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[7]  C K Redmond,et al.  Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. , 1999, Journal of the National Cancer Institute.

[8]  M. Espié,et al.  [Hormonal replacement therapy in menopause after breast cancer: first french study]. , 1998, Contraception, fertilite, sexualite.

[9]  E. Vittinghoff,et al.  Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. , 1998, JAMA.

[10]  J. Stanford,et al.  Risk of recurrence after ductal carcinoma in situ of the breast. , 1998, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[11]  T. Powles,et al.  Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial , 1998, The Lancet.

[12]  G. Colditz,et al.  Relationship between estrogen levels, use of hormone replacement therapy, and breast cancer. , 1998, Journal of the National Cancer Institute.

[13]  M. Beckmann,et al.  Hormonersatztherapie (HRT) nach Mammakarzinomerkrankung : Ergebnisse einer Beobachtungsstudie , 1998 .

[14]  M. Baum,et al.  Hormone Replacement Therapy in Women with Previous Breast Cancer , 1998, Trends in Endocrinology & Metabolism.

[15]  E. Beller,et al.  A cohort study of hormone replacement therapy given to women previously treated for breast cancer. , 1998, Climacteric : the journal of the International Menopause Society.

[16]  E. Negri,et al.  Hysterectomy, Oophorectomy in Premenopause, and Risk of Breast Cancer , 1997, Obstetrics and gynecology.

[17]  R. Theriault,et al.  Estrogen replacement therapy in women with prior diagnosis and treatment for breast cancer , 1997, Gynecologic oncology.

[18]  S. Cummings,et al.  Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures , 1996, The Lancet.

[19]  Kenneth K Wang,et al.  Esophagitis associated with the use of alendronate. , 1996, The New England journal of medicine.

[20]  R. Vassilopoulou-sellin,et al.  Estrogen replacement therapy after treatment for localized breast carcinoma: Patient responses and opinions , 1996, Cancer.

[21]  J. Eden,et al.  Hormone replacement therapy after breast cancer: a review. , 1996, Cancer treatment reviews.

[22]  Gambrell Rd.  Hormone replacement therapy and breast cancer risk. , 1996, Archives of family medicine.

[23]  H. Anton-Culver,et al.  Hormone replacement therapy in breast cancer survivors: a cohort study. , 1996, American journal of obstetrics and gynecology.

[24]  J. G. Schuler,et al.  The new era in breast cancer. Invasion, size, and nodal involvement dramatically decreasing as a result of mammographic screening. , 1996, Archives of surgery.

[25]  P. Disaia,et al.  Replacement therapy for breast cancer survivors. A pilot study , 1995, Cancer.

[26]  K. Helzlsouer,et al.  Prevalence of menopausal symptoms among women with a history of breast cancer and attitudes toward estrogen replacement therapy. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  G A Colditz,et al.  The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. , 1995, The New England journal of medicine.

[28]  T. Bush,et al.  A Case‐Control Study of Combined Continuous Estrogen—Progestin Replacement Therapy among Women with a Personal History of Breast Cancer , 1995 .

[29]  N. Robert,et al.  Estrogen Replacement Therapy in Breast Cancer Survivors: A Time for Change , 1994 .

[30]  J. Chmiel,et al.  1991 national survey of carcinoma of the breast by the Commission on Cancer. , 1994, Journal of the American College of Surgeons.

[31]  R. Theriault,et al.  Randomized prospective trial of estrogen-replacement therapy in women with a history of breast cancer. , 1994, Journal of the National Cancer Institute. Monographs.

[32]  P. Disaia,et al.  Hormone replacement therapy In breast cancer , 1993, The Lancet.

[33]  T. Powles,et al.  Hormone replacement after breast cancer , 1993, The Lancet.

[34]  R. Opfell,et al.  Hormone replacement therapy in previously treated breast cancer patients. , 1993, American journal of surgery.

[35]  J. Manson,et al.  Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study. , 1991, The New England journal of medicine.

[36]  E. Barrett-Connor,et al.  Estrogen and coronary heart disease in women , 1991, JAMA.

[37]  B. Stoll,et al.  Hormone replacement therapy in women treated for breast cancer. , 1989, European journal of cancer & clinical oncology.

[38]  R. Hoover,et al.  Menstrual factors and risk of breast cancer. , 1988, Cancer investigation.

[39]  W. Willett,et al.  Menopause and the risk of coronary heart disease in women. , 1987, The New England journal of medicine.

[40]  L. Melton,et al.  Relative contributions of aging and estrogen deficiency to postmenopausal bone loss. , 1984, The New England journal of medicine.

[41]  J R Beck,et al.  A convenient approximation of life expectancy (the "DEALE"). II. Use in medical decision-making. , 1982, The American journal of medicine.

[42]  B. Henderson,et al.  Menopausal estrogen therapy and hip fractures. , 1981, Annals of internal medicine.

[43]  W. Collins,et al.  ENDOCRINE CHANGES AND SYMPTOMATOLOGY AFTER OOPHORECTOMY IN PREMENOPAUSAL WOMEN , 1977, British journal of obstetrics and gynaecology.

[44]  Holleb Ai,et al.  The relation of carcinoma of the breast and pregnancy in 283 patients. , 1962 .

[45]  M. Peters.  Carcinoma of the breast associated with pregnancy. , 1962, Radiology.